Cumberland Pharmaceuticals Company Description
Cumberland Pharmaceuticals wants to make your search for the right drugs less cumbersome. The specialty pharmaceutical company focuses on acquiring, developing, and commercializing branded prescription drugs. Targeting the hospital acute care and gastroenterology segments, Cumberland's portfolio is comprised of two products (Acetadote, for the treatment of acetaminophen poisoning, and Kristalose, a prescription strength laxative) approved by the FDA, one candidate (Amelior, for the treatment of pain and fever) nearing completion of Phase III clinical trials, and several early-stage development projects. Acetadote and Kristalose are marketed through Cumberland's own hospital and gastroenterology sales forces.
View the Comprehensive Company Description for Cumberland Pharmaceuticals
The Company Description provides a historical perspective of Cumberland Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Cumberland Pharmaceuticals's evolution in the marketplace.
